# Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

> **NCT06782139** · PHASE4 · RECRUITING · sponsor: **Korea University Anam Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Obesity and Type 2 Diabetes

## Interventions

- **DRUG:** Enavogliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06782139
- **Lead sponsor:** Korea University Anam Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06782139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06782139, "Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06782139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*